Skip to main content
PMC home page
Immunology logoLink to Immunology
. 1988 Oct;65(2):299–303.

gp 58/68, a parasite component that contributes to the escape of the trypomastigote form of T. cruzi from damage by the human alternative complement pathway.

E Fischer 1, M A Ouaissi 1, P Velge 1, J Cornette 1, M D Kazatchkine 1
PMCID: PMC1384928  PMID: 2973433

Abstract

A glycoprotein of apparent molecular weight 58,000 (unreduced)/68,000 (in its reduced form) (gp 58/68), which is one of the fibronectin/collagen receptors of Trypanosoma cruzi, was purified to homogeneity from the trypomastigote forms of the Tehuantepec and Y strains of the parasite. Purified gp 58/68 inhibited formation of cell-bound and fluid-phase alternative pathway C3 convertase in a dose-dependent fashion, as assessed using purified human complement components. Gp 58/68 differed from the human regulatory proteins H, DAF, MCP and CR1 and from previously reported regulatory proteins on the parasite membrane in that it was unable to enhance decay-dissociation of preformed alternative pathway C3 convertase sites, did not serve as a co-factor for I-mediated cleavage of C3b and had no inhibitory activity on the classical pathway convertases. The inhibitory effect of gp 58/68 was most likely dependent on an interaction of the protein with factor B rather than with C3b. Gp 58/68 provides trypomastigotes with an additional potential mechanism for escaping complement lysis by the human alternative pathway.

Full text

PDF
300

Images in this article

301Figure 1
on p.301

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Fearon D. T., Austen K. F. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A. 1977 Apr;74(4):1683–1687. doi: 10.1073/pnas.74.4.1683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fearon D. T., Austen K. F. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med. 1975 Oct 1;142(4):856–863. doi: 10.1084/jem.142.4.856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fearon D. T. Purification of C3b inactivator and demonstration of its two polypeptide chain structure. J Immunol. 1977 Oct;119(4):1248–1252. [PubMed] [Google Scholar]
  4. Fearon D. T. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci U S A. 1978 Apr;75(4):1971–1975. doi: 10.1073/pnas.75.4.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fischer E., Capron M., Prin L., Kusnierz J. P., Kazatchkine M. D. Human eosinophils express CR1 and CR3 complement receptors for cleavage fragments of C3. Cell Immunol. 1986 Feb;97(2):297–306. doi: 10.1016/0008-8749(86)90400-4. [DOI] [PubMed] [Google Scholar]
  6. Fischer E., Kazatchkine M. D. Surface-dependent modulation by H of C5 cleavage by the cell-bound alternative pathway C5 convertase of human complement. J Immunol. 1983 Jun;130(6):2821–2824. [PubMed] [Google Scholar]
  7. Iida K., Nussenzweig V. Complement receptor is an inhibitor of the complement cascade. J Exp Med. 1981 May 1;153(5):1138–1150. doi: 10.1084/jem.153.5.1138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Joiner K., Hieny S., Kirchhoff L. V., Sher A. gp72, the 72 kilodalton glycoprotein, is the membrane acceptor site for C3 on Trypanosoma cruzi epimastigotes. J Exp Med. 1985 May 1;161(5):1196–1212. doi: 10.1084/jem.161.5.1196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Joiner K., Sher A., Gaither T., Hammer C. Evasion of alternative complement pathway by Trypanosoma cruzi results from inefficient binding of factor B. Proc Natl Acad Sci U S A. 1986 Sep;83(17):6593–6597. doi: 10.1073/pnas.83.17.6593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jouvin M. H., Kazatchkine M. D., Cahour A., Bernard N. Lysine residues, but not carbohydrates, are required for the regulatory function of H on the amplification C3 convertase of complement. J Immunol. 1984 Dec;133(6):3250–3254. [PubMed] [Google Scholar]
  11. Kipnis T. L., David J. R., Alper C. A., Sher A., da Silva W. D. Enzymatic treatment transforms trypomastigotes of Trypanosoma cruzi into activators of alternative complement pathway and potentiates their uptake by macrophages. Proc Natl Acad Sci U S A. 1981 Jan;78(1):602–605. doi: 10.1073/pnas.78.1.602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kipnis T. L., Tambourgi D. V., Sucupira M., Dias-da-Silva W. Effect of Trypanosoma cruzi membrane components on the formation of the classical pathway C3 convertase. Braz J Med Biol Res. 1986;19(2):271–278. [PubMed] [Google Scholar]
  13. Medof M. E., Kinoshita T., Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med. 1984 Nov 1;160(5):1558–1578. doi: 10.1084/jem.160.5.1558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Morrissey J. H. Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity. Anal Biochem. 1981 Nov 1;117(2):307–310. doi: 10.1016/0003-2697(81)90783-1. [DOI] [PubMed] [Google Scholar]
  15. Nicholson-Weller A., Burge J., Fearon D. T., Weller P. F., Austen K. F. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol. 1982 Jul;129(1):184–189. [PubMed] [Google Scholar]
  16. Nogueira N., Bianco C., Cohn Z. Studies on the selective lysis and purification of Trypanosoma cruzi. J Exp Med. 1975 Jul 1;142(1):224–229. doi: 10.1084/jem.142.1.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ouaissi M. A., Cornette J., Capron A. Identification and isolation of Trypanosoma cruzi trypomastigote cell surface protein with properties expected of a fibronectin receptor. Mol Biochem Parasitol. 1986 Jun;19(3):201–211. doi: 10.1016/0166-6851(86)90002-2. [DOI] [PubMed] [Google Scholar]
  18. Schenkman S., Güther M. L., Yoshida N. Mechanism of resistance to lysis by the alternative complement pathway in Trypanosoma cruzi trypomastigotes: effect of specific monoclonal antibody. J Immunol. 1986 Sep 1;137(5):1623–1628. [PubMed] [Google Scholar]
  19. Seya T., Turner J. R., Atkinson J. P. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med. 1986 Apr 1;163(4):837–855. doi: 10.1084/jem.163.4.837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sher A., Hieny S., Joiner K. Evasion of the alternative complement pathway by metacyclic trypomastigotes of Trypanosoma cruzi: dependence on the developmentally regulated synthesis of surface protein and N-linked carbohydrate. J Immunol. 1986 Nov 1;137(9):2961–2967. [PubMed] [Google Scholar]
  21. Tack B. D., Prahl J. W. Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry. 1976 Oct 5;15(20):4513–4521. doi: 10.1021/bi00665a028. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES